Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gastrointestinal tumours, colorectal 1

5247 - 1st-line mFOLFOXIRI + Panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109).


20 Oct 2018


Poster Discussion session - Gastrointestinal tumours, colorectal 1


Cytotoxic Therapy;  Clinical Research

Tumour Site

Colon and Rectal Cancer


Michael Geissler


Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


M. Geissler1, T. Klingler1, J. Riera Knorrenschild2, A. Tannapfel3, J. Greeve4, T. Seufferlein5, S. Kanzler6, S. Held7, V. Heinemann8, A. Reinacher-Schick9, U.M. Martens10

Author affiliations

  • 1 Internal Medicine, Oncology/hematology, Klinikum Esslingen, 73730 - Esslingen/DE
  • 2 Oncology, Uniklinikum Giessen und Marburg, 35043 - Marburg/DE
  • 3 Pathology, Ruhr-Universität Bochum, 44801 - Bochum/DE
  • 4 Gastroenterology, St. Vincenz Krankenhaus, Paderborn/DE
  • 5 Department Of Internal Medicine I  , Ulm Medical University, 89081 - Ulm/DE
  • 6 Department Of Internal Medicine Ii, Leopoldina Krankenhaus Schweinfurt, Schweinfurt/DE
  • 7 Statistik, Clinassess, 51379 - Leverkusen/DE
  • 8  department Of Medical Oncology And Comprehensive Cancer Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 9 Oncology, Ruhr University Bochum Medizinische Universitätsklinik, 44892 - Bochum/DE
  • 10 Oncology, SLK-Kliniken Heilbronn GmbH, 74078 - Heilbronn/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5247


This trial evaluated activity and safety of mFOLFOXIRI + panitumumab vs FOLFOXIRI in ECOG 0-1, primarily non-resectable mCRC patients.


Prospective 2:1 randomized, multi-center, phase II trial comparing mFOLFOXIRI (Ox 85, Iri 150, 5-FU 3000, LV 200) + Panitumumab 6 mg/KG (arm A) with FOLFOXIRI (Ox 85, Iri 165, 5-FU 3200 cont. 48h, LV 200; arm B). Cohort 1: irresectable mCRC; cohort 2: chance of secondary resection of metastatic lesions. Primary endpoint: ORR, secondary endpoints: secondary resection rate, DCR, PFS, OS, toxicity, QL (QLQ-C30). Financially supported by an unrestricted grant from Amgen.


A total of 96 patients were randomized (63 arm A, 33 arm B). After an observation time of 29 months in both arms, final ORR results are displayed in the table. PFS in arm A reached 9.7 mo, in arm B 10.1 mo (HR 0.92, p=n.s.). PFS cohort II was 13.0 vs 9.0 mo in arm A and B, respectively (HR0.457, p = 0.068). PFS in BRAF mutated was comparable between arm A and B (6.5 vs 6.1 mo, HR 1.368, n.s.). Secondary resections were achieved in 33.3% (arm A) and 12.1% (arm B), R0 in 61.9% vs. 75.0%, respectively. In cohort 1, resections were achieved in 14% vs 0%, in cohort 2 in 75% vs 36.4%. RFS after resection of metastases was 7.9 vs 4.0 months in arm A and B, respectively (HR 0.623, p=n.s.). Treatment related adverse advents grade 3-5 occured in 81.3% and 66.7% in arms A and B, respectively (p = 0.1336). Non.haematological AEs grade 3-5 were more frequent in arm A (71.9%) than in arm B (39.4%), p = 0.0039. Nevertheless, no differences in global health status, functional scales, and symptom scales were reported.Table: 453PD

mFOLFOXIRI +PmabFOLFOXIRIp-valueOdds Ratio95%-CI
ITT, n = 9687.360.60.00414.4691.614-12.376
Cohort II, n = 31100.063.30.010524.61.1778-513.8
Left, n = 7890.668.00.02104.5181.298-15.718
Right, n = 1870.037.50.34163.8890.543-27.886
RAS/BRAF wt, n = 6086.064.70.08063.3640.902-12.549
BRAF mut, n = 1685.722.20.040621.0001.504-293.25


mFOLFOXIRI + Panitumumab results in significantly higher ORR compared to FOLFOXIRI. Strong effectivity was observed also in right sided and BRAF mutated CRC. High secondary resection rates could be achieved. Although toxicity (treatment related SAEs) was increased, QL reporting was similar in both arms. OS is still immature, but will be presented first time at the meeting.

Clinical trial identification


Legal entity responsible for the study

AIO Studien GmbH.



Editorial Acknowledgement


M. Geissler: Honararium, advisory boards: Amgen, Sanofi, Merck, Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.